These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21350792)

  • 1. Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment.
    Tfelt-Hansen P
    J Headache Pain; 2011 Jun; 12(3):275-80. PubMed ID: 21350792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis.
    Cui XP; Ye JX; Lin H; Mu JS; Lin M
    Pain Pract; 2015 Feb; 15(2):124-31. PubMed ID: 24382126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
    Ho TW; Ferrari MD; Dodick DW; Galet V; Kost J; Fan X; Leibensperger H; Froman S; Assaid C; Lines C; Koppen H; Winner PK
    Lancet; 2008 Dec; 372(9656):2115-23. PubMed ID: 19036425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.
    Tfelt-Hansen P
    Headache; 2011 Jan; 51(1):118-23. PubMed ID: 21070229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.
    Dodick DW; Kost J; Assaid C; Lines C; Ho TW
    Cephalalgia; 2011 Feb; 31(3):296-300. PubMed ID: 20937606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment.
    Tfelt-Hansen PC
    J Headache Pain; 2009 Dec; 10(6):389-91. PubMed ID: 19779958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Triptans and calcitonin gene-related peptide (CGRP) receptor antagonists].
    Negoro K
    Rinsho Shinkeigaku; 2012; 52(11):971-2. PubMed ID: 23196486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CGRP receptor antagonists: an expanding drug class for acute migraine?
    Negro A; Lionetto L; Simmaco M; Martelletti P
    Expert Opin Investig Drugs; 2012 Jun; 21(6):807-18. PubMed ID: 22512641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimigraine efficacy of telcagepant based on patient's historical triptan response.
    Ho TW; Olesen J; Dodick DW; Kost J; Lines C; Ferrari MD
    Headache; 2011 Jan; 51(1):64-72. PubMed ID: 21054362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 5-HT
    Whealy M; Becker WJ
    Handb Clin Neurol; 2024; 199():17-42. PubMed ID: 38307644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.
    Dodick DW; Sandrini G; Williams P
    CNS Drugs; 2007; 21(1):73-82. PubMed ID: 17190530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial.
    Connor KM; Aurora SK; Loeys T; Ashina M; Jones C; Giezek H; Massaad R; Williams-Diaz A; Lines C; Ho TW
    Headache; 2011 Jan; 51(1):73-84. PubMed ID: 21070230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptans for the management of migraine.
    Johnston MM; Rapoport AM
    Drugs; 2010 Aug; 70(12):1505-18. PubMed ID: 20687618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CGRP antagonists: hope for a new era in acute migraine treatment.
    Schelstraete C; Paemeleire K
    Acta Neurol Belg; 2009 Dec; 109(4):252-61. PubMed ID: 20120204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACS chemical neuroscience molecule spotlight on Telcagepant (MK-0974).
    Hopkins CR
    ACS Chem Neurosci; 2011 Jul; 2(7):334-5. PubMed ID: 22816019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists.
    Hougaard A; Tfelt-Hansen P
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1409-18. PubMed ID: 26095133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical use of triptans in the management of migraine].
    Lantéri-Minet M
    CNS Drugs; 2006; 20 Spec no.1():12-23. PubMed ID: 16841523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
    McCormack PL; Foster RH
    Pharmacoeconomics; 2005; 23(12):1283-98. PubMed ID: 16336021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
    Tfelt-Hansen P; De Vries P; Saxena PR
    Drugs; 2000 Dec; 60(6):1259-87. PubMed ID: 11152011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine.
    Tepper SJ; Cleves C
    Curr Opin Investig Drugs; 2009 Jul; 10(7):711-20. PubMed ID: 19579177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.